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Abstract
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by 
phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast 
growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting syndrome. Upon 
complete surgical removal of the tumor, FGF-23 normalizes and the osteomalacia is cured. In 
cases in which surgery is not feasible, radiofrequency ablation (RFA) is the treatment of choice. 
We describe a case with a PMT situated in the sacrum, in close proximity to the sacral plexus. 
Both surgery and RFA were considered potentially nerve damaging. Since the tumor showed 
expression of somatostatin receptors, we opted for a peptide receptor radionuclide therapy 
(PRRT) with 177Lu-DOTATOC. However, the therapy did not show the expected success, since 
the FGF-23 level had even temporarily increased. The patient was then successfully treated 
with RFA. A partial remission of the tumor was achieved and FGF-23 levels nearly normalized. 
Despite some severe neurological side effects, the patient showed a remarkable clinical im-
provement, with no symptoms of osteomalacia within a few weeks.
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Introduction
Phosphaturic mesenchymal tumors (PMTs) are rare, endocrine active tumors. They 
cause severe renal phosphate wasting, which in turn can lead to critical osteomalacia [1]. 
PMTs are typically small and mostly benign tumors [2] producing fibroblast growth factor 23 
(FGF-23) [3]. FGF-23 lowers the expression of sodium/phosphate cotransporters (NaPi-IIa/
NaPi-IIc) [4], which are the primary transport proteins responsible for phosphate reab-
sorption in the kidneys [3]. The paraneoplastic overproduction of FGF-23 lowers reabsorption 
of phosphate and causes severe paraneoplastic renal phosphate wasting and hypophospha-
temia [1]. FGF-23 also affects vitamin D levels by lowering 25-hydroxyvitamin D 1-alpha-
hydroxylase in the proximal renal tubules and by increasing the expression of vitamin D 
24-hydroxylase, a mitochondrial enzyme responsible for inactivating vitamin D metabolites 
[4].
Patients with PMT suffer from unspecific but progressive symptoms such as bone and 
muscle pain, and are therefore commonly misdiagnosed with rheumatic (e.g., seronegative 
rheumatoid arthritis) or neuropsychiatric illnesses [2, 5]. In most cases, it takes up to 5 years 
until the correct diagnosis is made [6]. Since phosphate levels are not tested regularly, patho-
logical fractures due to loss of bone density, which occur after several years of pain, are often 
a key symptom leading to the diagnosis [1].
PMT typically demonstrates expression of somatostatin receptors. Therefore, if a PMT is 
suspected and a high serum FGF-23 level has been shown, patients may undergo 68Ga-DOTA-
octreotate (DOTATATE) PET/CT to locate the tumor [7]. The tumor occurs mainly in bones 
(40%) and soft tissues (55%), and may be located in the thighs and femurs (22.7%), cranio-
facial region (20.7%), ankles and feet (8.8%), pelvis (8.2%), tibiae and fibulae (6.5%), and 
arms (6.5%) [3].
To reduce symptoms, a substitution of phosphate and vitamin D can be initiated. Standard 
care is the surgical removal of the tumor. After the tumor has been removed and the FGF-23 
level has normalized, the symptoms disappear and most patients recover quickly [2]. If 
surgical removal is not feasible, radiofrequency ablation (RFA) or cryoablation seem to be the 
best options, and they have been performed successfully in several cases [8]. So far, there has 
been no gold standard for systemic treatment if a surgical or interventional approach is 
impossible.
The somatostatin receptor expression observed in PMT suggests use of the somatostatin 
analog octreotide. Octreotide binds to the somatostatin receptor and could therefore down-
regulate the endocrine activity of PMT cells – similar to neuroendocrine tumors (NETs). In 
2001, a case was reported with a short neoadjuvant octreotide intervention before surgical 
removal of a PMT. Brief normalization of renal phosphate clearance was achieved [9]. The use 
of octreotide, however, remains controversial. First, the therapy in the case above was used 
only for a limited time. Second, 2 subsequently reported cases could not confirm these results. 
Neither of these cases showed a clinical or biochemical response. Thus, the current value of 
octreotide for the treatment of PMT remains unclear [10, 11].
Similarly to PMTs, NETs, which are much more prevalent tumors, express high levels of 
somatostatin receptors. Metastatic NET can be treated successfully with peptide receptor 
radionuclide therapy (PRRT), using 177Lu- or 90Y-DOTATOC. In PRRT, the somatostatin 
receptor is targeted with a radionucleotide conjugated to a somatostatin analog. Frequently, 
the beta emitter 177Lu is used as a radionucleotide. In the NETTER-1 trial – a randomized 
phase III study with a total of 229 patients – the overall response rate to PRRT was 18% [12].
So far there have only been few published cases of patients undergoing PRRT for the 
treatment of PMT [13, 14]. Due to the lack of data, it is currently uncertain if or when an 
experimental approach with PRRT is a promising option.
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Case Report
Our 58-year-old male patient and former marathon runner had a history of nearly 10 
years of increasing lower back and joint pain. He was diagnosed with and treated for sero-
negative rheumatoid arthritis. However, the symptoms got worse and he developed muscle 
pain, paresthesias, and increasing concentration difficulties. Ultimately his performance 
status became very poor and he had to move into a wheelchair-accessible house.
After the patient’s back pain had worsened to an unacceptable level without any adequate 
trauma, his new general practitioner decided to question the diagnosis and ordered a new 
panel of diagnostic tests.
An MRI of the thoracic and lumbar spine and pelvis revealed a 5-cm-large bone lesion in 
the sacrum, and metastatic malignancy was suspected. The sacral bone lesion had direct 
contact to the neuroforamina of S1 and S2 and reached into the canalis sacralis, also affecting 
the plexus sacralis.
A CT scan and a bone scintigraphy showed several pathological fractures of different age 
but no evidence of any metastatic malignancy. The known bone lesion in the sacrum was 
Fig. 1. Whole-body bone scintig-
raphy showing multiple patholog-
ical fractures.
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unspecific, and no discrimination between a pathological fracture and a tumor could be made. 
Further diagnostics were needed (Fig. 1).
A biopsy was performed and a preliminary diagnosis of PMT was put forward. With an 
elevated serum FGF-23 level of 215 kRU/L (Ref. 26–110) and a low serum phosphate level of 
0.3 mmol/L (Ref. 0.74–1.52), the diagnosis was confirmed. A 68Ga-DOTATATE-PET-CT – the 
most specific diagnostic imaging for a PMT – showed a solitary tumor in the sacrum measuring 
5 × 5 × 5 cm and being highly 68Ga-DOTATATE avid, without any other manifestations.
Standard therapy – surgical removal – was not feasible without severe nerve damage that 
would have resulted in bladder, rectal and sexual dysfunction. RFA was initially considered 
too risky for the same reasons. Phosphate and calcitriol supplementation was initiated to 
diminish the symptoms.
After considering all the available options and in view of the high avidity to somatostatin 
on 68Ga-DOTATATE-PET, we opted for an experimental 177Lu-DOTATOC treatment. Over a 
period of 6 months, a total of 4 therapies were administered (Table 1). During the first 
treatment cycle, tumor dosimetry was done, which revealed a tumor dose of 9.7 Gy after 
injection of 7.2 GBq 177Lu-DOTATOC. After the 4 cycles of PRRT, another 68Ga-DOTATATE-
PET-CT was performed, which showed stable disease, with an identical tumor size and gallium 
uptake (SUV 26.5 before and 26.3 after treatment) (Fig. 2).
During PRRT, the FGF-23 level temporarily increased from around 200 to over 400 
kRU/L (Ref. 26–110). It is likely that a tumor lysis syndrome was involved in this increase, as 
the FDF-23 values slowly decreased after termination of the 177Lu-DOTATOC treatment. 
However, FGF-23 remained above the normal level and the phosphate waste continued, 
which led us to the conclusion that the therapy did not show the expected success (Fig. 3).
Even though the substitution therapy could improve the symptoms, the patient still 
suffered from fatigue and had a reduced quality of life. Unfortunately, we had to conclude that 
the 177Lu-DOTATOC treatment had failed.
Time point Substance Dosage
Week 0 177Lu-DOTATOC 7.2 GBq (9.7 Gy)
Week 9 177Lu-DOTATOC 7.1 GBq
Week 19 177Lu-DOTATOC 5.7 GBq
Week 29 177Lu-DOTATOC 6.9 GBq
Total 177Lu-DOTATOC 26.9 GBq
Table 1. 177Lu-DOTATOC 
regimen used
Fig. 2. 68Ga-DOTATATE-PET before (left) and after (right) peptide receptor radionuclide therapy, with no 
difference in tumor size and 68Ga-DOTATATE avidity.
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Due to the lack of any promising alternative, we reviewed the option of RFA. A first RFA 
was performed in May 2018. The approach was planned and performed successfully without 
damaging the nerves. A slight reduction of FGF-23 (from 315 to 225 kRU/L) and an increase 
to the low end of the normal range in the still substituted serum phosphate was seen, albeit 
without significant clinical improvement. On 68Ga-DOTATATE-PET-CT, only a minor reduction 
in size of less than 10% of the tumor volume was detectable.
Since the symptoms persisted, serum phosphate had again decreased to below the normal 
level even though substituted, and quality of life was still deemed insufficient, another RFA 
was attempted. The second RFA was more successful, resulting in partial remission of the 
tumor, from 5 × 5 × 5 cm to 1.9 × 0.6 × 2.7 cm.
The serum FGF-23 level had almost normalized to a level of 108 kRU/L and renal phos-
phate waste had stopped. The substitution therapy could be terminated. One year after the 
intervention, the tumor size remained in partial remission, serum FGF-23 was stable at 
Fig. 3. Serum fibroblast growth factor 23 (FGF-23; A) and serum phosphate (B) during the therapies.
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slightly above the low end of the normal range, and the phosphate level still was within the 
normal range without substitution. The patient still had a good quality of live without tumor-
related symptoms and an ongoing improvement of the tumor-induced osteomalacia.
Unfortunately, the second RFA had caused neurological damage. The patient suffered 
permanent loss of surface sensibility on both inner thighs and an acute bladder dysfunction. 
He also required a transurethral catheter due to urinary retention. After several unsuccessful 
attempts of voluntary voiding, a suprapubic catheter had to be put in place. Due to the neuronal 
impairment of the bladder, a previously asymptomatic prostate hyperplasia became symp-
tomatic. Following transurethral prostate resection, the patient is now able to release urine 
without a catheter again. Finally, a rectal dysfunction occurred, initially requiring enemas. At 
present, normal voiding is possible with laxatives. Despite these side effects, the patient 
recovered from the osteomalacia within a few weeks. Pain and muscle weakness disappeared 
completely, and the patient is now able to do sports again.
In conclusion, despite some serious neurological side effects, the quality of live improved 
dramatically.
Discussion
To the best of our knowledge, we reported the third case of PMT treated with 
177Lu-DOTATOC. Unfortunately, this treatment was not successful, the size of the tumor 
remained unchanged, and we found no relevant improvement in endocrine activity. In 
contrast, RFA led to partial remission of the tumor mass and to a significant reduction in 
endocrine activity, as measured by serum FGF-23 levels. This resulted in a remarkable symp-
tomatic improvement.
There are only 2 previously published reports of cases of DOTATOC therapy for PMT, and 
both describe some success using DOTATOC [13, 14]. The first paper describes a case of 
recurrent PMT with good symptomatic improvement and a reduction in SUV on both 
68Ga-DOTATATE-PET-CT and FDG-PET/CT upon 177Lu-DOTATOC treatment. According to 
the RECIST, only stable disease was achieved, but a clear clinical improvement was observed. 
Unfortunately, no post-treatment serum FGF-23 or phosphate levels were published [13].
The second case describes a metastatic PMT. After resection of the primary tumor in the 
tarsal region, the tumor was recurrent locally and metastases in both lungs were found. After 
resection of both metastases, a first 177Lu-DOTATATE therapy was initiated before ampu-
tation of the foot to treat micrometastases, and 3 more 177Lu-DOTATATE therapies were 
administered postoperatively. After the amputation and during the PRRT, a temporary 
normalization of serum phosphorus levels without supplementation was seen. No metastasis 
could be found on a 68Ga-DOTANOC-PET-CT scan after the 4 cycles of 177Lu-DOTATATE. 
However, the patient had to restart phosphorus supplementation 2 months after the last 
PRRT in order to maintain serum phosphorus levels within the normal range. This indicates 
that active micrometastases probably persisted after the PRRT. Additionally, it is possible 
that the temporary normalization of serum phosphate was to a large degree due to the ampu-
tation and not to the 177Lu-DOTATATE therapy [14].
There are some important differences between the 2 previously prescribed cases and our 
case. The tumors in the previous cases were locally recurrent and showed a potential to grow, 
and one even metastasized, whereas in our case the tumor remained stable in size over the 
whole observation period of more than 2 years. Thus, the former tumors presumably had a 
different and more malignant biology, whereas our case displayed the more typical benign 
course of PMT [2].
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In a recurrent and growing tumor, targeted radiotherapy might be more effective. The 
achievement of stable disease in such a case is a success, whereas in a nongrowing and benign 
tumor, radiotherapy is less likely to cause critical damage to the tumor. Stable disease as the 
best response represents the natural course and can be interpreted as ineffective treatment. 
Surgery, the standard treatment, was not feasible in this case due to the anatomical location 
of the PMT. RFA, the alternative therapeutic option, was very efficacious, even though several 
neurological side effects occurred.
At present, no other systemic treatment is available. KRN23, a newly designed investiga-
tional recombinant fully human monoclonal IgG1 antibody against the phosphaturic hormone 
FGF-23, is currently in clinical evaluation. Interim data from a phase II study published in 
April 2016 showed improved serum phosphorus levels and other bone metabolism measures. 
The study was then extended to 15 patients, but final data are pending [15].
PMT is a very rare entity. Most cases can be successfully treated with surgery or RFA. It 
will be very difficult to perform randomized prospective studies on relapsing or refractory 
PMTs. While there is an obvious rationale for treating these tumors with PRRT, the published 
case reports so far have shown no or only moderate efficacy of PRRT, since none of the 3 
patients were cured.
However, further cases will be needed to investigate whether and in which cases PRRT 
could be an option for treating PMTs. In this sense, our case provides an important, albeit 
negative, piece of evidence.
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